GSK hires Branson from Genentech to boost AI team

fiercebiotech | July 11, 2019

GlaxoSmithKline has bolstered its artificial intelligence team by hiring Kim Branson from Genentech. The appointment gives Branson oversight of GSK’s efforts to use AI to find novel drug targets. Branson headed up AI at Genentech’s early clinical development unit for about a year before joining GSK recently as global head of artificial intelligence and machine learning. The appointment is the latest in a series of moves by GSK designed to revitalize its R&D operation through the use of technology. “The most impactful way any company will change its performance is making the timelines shorter, the costs lower and the probability of success higher,” GSK CEO Emma Walmsley told Bloomberg, the first publication to report news of Branson’s appointment. Branson arrives at GSK following a career spent straddling the line between drug development and computing. Early in his career, Branson spent two years at computational drug design pioneer Vertex before sidestepping into health data and analytics at Gliimpse—which Apple acquired—and Lumiata. Genentech attracted Branson back into biopharma in 2018 but was unable to keep hold of him for long. At GSK, Branson has joined up with a growing pool of Genentech alumni led by Hal Barron. Some of the changes made to GSK’s R&D group under Barron and Walmsley have related to AI. Months after Walmsley took over as CEO, GSK formed a pact with AI-enabled drug discovery shop Exscientia. Around the same time, GSK put John Baldoni in charge of new AI-focused group and teamed up with Insilico Medicine. In 2018, GSK joined forced with another AI startup, Cloud Pharmaceuticals.

Spotlight

A single mold can make tens of thousands of seed-like spores, which you can't see. But that's just one reason why mold is so difficult to control.

Spotlight

A single mold can make tens of thousands of seed-like spores, which you can't see. But that's just one reason why mold is so difficult to control.

Related News

INDUSTRIAL IMPACT

Inventors of biolayer interferometry technology launch a next gen platform and novel biosensors

Gator Bio | September 15, 2021

Gator Bio, Inc. announced today the launch of the GatorPlus, a next generation biolayer interferometry (BLI) instrument and two new biosensor products, Gator™ Flex SA Kit and Gator™ AAVX probe. The GatorPlus adds to the currently available GatorPrime instrument; and the new Gator™ Flex SA Kit and Gator™ AAVX probe expand the off the shelf biosensor portfolio to 14 products for the North America market. Gator Bio also offers on demand custom biosensors for specific application needs. GatorPlus is a bench-top instrument for real-time label-free analysis of molecular interactions and quantitation in 96-well or 384-well microplates. The instrument offers longer walk-away time and more automation compared to GatorPrime, the first Gator instrument launched in March 2019. Based on Gator Bio's proprietary technology, the Gator™ Flex SA Kit is the industry's first ever reactivable streptavidin biosensor for BLI. It can be reactivated and reused more than 20 times without performance degradation, enabling significant cost saving for Gator system customers. The Gator™ AAVX probe quantitates many serotypes of AAVs automatically in minutes, greatly simplifying AAV developers' workflow. The results obtained from the Gator™ AAVX probes correlate tightly to the gold standard method. Gator Bio was founded by Dr. Hong Tan and Mr. Robert Zuk, the pioneers of biolayer interferometry. The company has been focused on development and commercialization of the next generation BLI that greatly enhances the performance and cost effectiveness of this simple yet powerful analytical technology. In addition to the newly introduced Gator™ Flex SA Kit and Gator™ AAVX probes, Gator Bio offers a wide range of products, including the highly sensitive SMAP biosensor and the regenerable mouse Fc capture biosensor. The Gator systems and associated biosensors provide convenient kinetic analysis and concentration determination for the development of antibody and protein therapeutics. "We saw problems and shortcomings with the original BLI technology, so we decided to come back to close the gaps with new ways to realize BLI. Our objective is to enable the most effective and efficient BLI systems for scientists". - Dr. Hong Tan, CEO of Gator Bio. About Gator Bio,Inc. Gator Bio is a life sciences company providing bioanalytical systems to accelerate the development of therapeutics and diagnostics. Gator Bio along with its sister company ET Healthcare are part of Access Medical Systems. The Gator instruments and biosensors enable real-time analysis of biomolecular interactions providing information on affinity, kinetics, concentration and epitope binning, etc. Most importantly, Gator Bio's analytical capabilities enable better and faster characterization of drug candidates, thus providing greater value in drug development applications where existing methods have limitations in throughput, performance, and cost. The company is headquartered in Palo Alto, California with facilities in Shanghai and Suzhou, China.

Read More

CELL AND GENE THERAPY

Tevard Biosciences and Zogenix Collaborates to Identify and Develop Novel tRNA-based Gene Therapies for Dravet Syndrome and other Genetic Epilepsies

Tevard Biosciences | December 04, 2020

Tevard Biosciences, a privately-held biotechnology organization pioneering tRNA-based gene therapies, and Zogenix, a worldwide biopharmaceutical organization creating and commercializing uncommon infection treatments, today reported that the organizations have gone into a cooperation to recognize and create novel tRNA-based quality treatments for Dravet syndrome and other genetic epilepsies. Under the collaboration, Tevard will use its two interesting tRNA-based discovery platforms focused with respect to mRNA Stabilization and Nonsense Codon Suppression to find and advance novel drug candidates for the treatment of Dravet condition and other genetic epilepsies. Zogenix will additionally build up the up-and-comers through cutting edge preclinical examinations and clinical turn of events, and be responsible for overall commercialization.

Read More

MEDTECH

Novozymes and Saipem enter collaboration agreement to create a more sustainable CO2 capture

Novozymes | December 13, 2021

Novozymes, the world leader in biological solutions, and Saipem, an advanced technological and engineering platform for safe and sustainable complex infrastructure and plants, have signed a collaboration agreement for the development of innovative solutions for enzymatic carbon capture. As part of the agreement, Saipem - which owns an enzyme-based CO2 capture technology - will be responsible for providing process, mechanical and equipment design, while Novozymes will provide enzymes while further optimizing the process through enzymes innovation. Enzymatic carbon capture is more sustainable in environmental terms and more cost-effective compared to traditional CO2 capture processes. In fact, it is based on the use of enzymes that require the input of heat at lower temperatures and a significantly moderate use of chemicals, energy and, consequently, cuts down the production of harmful waste. Furthermore, this process is more reliable, as the carbonates and enzymes, being low corrosion materials, minimize the deterioration of equipment. Saipem and Novozymes are mutually satisfied with the signed agreement which constitutes an important step towards realizing innovative solutions for the reduction of greenhouse gas emissions. In fact, thanks to Saipem's expertise in CO2 capture and storage technologies and Novozymes' cutting-edge enzymes solutions, the two companies can make the enzymatic carbon capture process highly competitive on the market of traditional amine processes. “This collaboration is an important step towards more sustainable solutions for lowering greenhouse gas emissions. Enzymatic carbon capture has the potential to replace resource-heavy processes with energy-efficient, biological processes, providing both environmental and financial benefits while accelerating the battle against climate change,” Amy Byrick, Executive Vice President of Strategy & Business Transformation at Novozymes About Novozymes Novozymes is the world leader in biological solutions. Together with customers, partners, and the global community, we improve industrial performance while preserving the planet's resources and helping build better lives. As the world's largest provider of enzyme and microbial technologies, our bioinnovation enables higher agricultural yields, low-temperature washing, energy-efficient production, renewable fuel, and many other benefits that we rely on today and in the future.

Read More